Plant extract from low-THC Cannabis for the treatment of disease US 8337908 B2

«In the scope of this invention, a “low-tetrahydrocannabinol (THC) variety” is understood as a variety which, in such a plant extract, has less than 5%, preferably less than 2%, in particular less than 0.5 to 0.2% or down to 0.1 or 0% (wt.-%) THC content. In particular, these quantities of THC are to be understood as not representing a clinically relevant concentration.

Surprisingly, it has been shown by the experiments performed in the scope of the invention that this plant extract has an effectiveness comparable or even superior to cortisone and calcineurin (without their side effects!) in regard to diseases of the allergically and immunologically related spectrum disorder. In patients having neurodermitis, which has a highly dramatic clinical course, the need, which is in the foreground for almost all patients, for itching relief could be dramatically improved in particular in comparison to the previously ordered cortisone or calcineurin inhibitors. The clinical relevance results from the secondary results of this cardinal guiding symptom for neurodermitis: scratching until bloody at the affected skin areas because of the unrelieved itch, with consequent lichenification. In contrast to the symptom influence (itching), which only begins within days after cortisone therapy, the guiding symptom of itching can be improved within a few minutes using the low-THC plant extract in a pharmaceutically suitable administration form. Through this improvement of the clinical symptom “itching”, which is in the foreground, secondary symptoms such as scratch-related skin lesions with bleeding, followed by subsequent lichenification, are clinically visibly improved within a few days. This is of very high significance above all for women and/or in the facial area.

In addition, this plant extract has not displayed any side effects up to this point. Therefore, all of the above-mentioned side effects under the treatment using cortisone or calcineurin inhibitors are not a concern and/or may even be healed, in particular in regard to the topical side effects of longer cortisone therapy. The use of cortisone and calcineurin can be completely avoided. […]

According to the surprising effectiveness of the plant extract of the present invention described above, this extract is also used for the production of a pharmaceutical, preferably for the treatment of neurodermitis, contact eczema, allergies, the prevention or treatment of phototoxic reactions, the treatment of inflammatory, itching dermatoses, rosacea, perioral dermatitis, acne, acne conglobata, psoriasis (vulgaris, arthropathica, pustulosa), mosquito bites, skin atrophy (in particular also cortisone-related skin changes), allergic rhinitis, privinismus, conjunctivitis, otitis externa, bronchial asthma, Crohn’s disease, ulcerative colitis, sarcoidosis, or inflammatory-rheumatic diseases of the soft tissue or joints, and mycoses. Inflammatory, itching dermatoses in the meaning of the present invention are understood in particular as diseases selected from the group comprising rosacea, perioral dermatitis, psoriasis vulgaris, psoriasis pustulosa, acne, acne conglobata.

Inflammatory-rheumatic diseases in the meaning of the present invention are understood as diseases selected from the group comprising chronic polyarthritis, Bechterew’s disease, psoriasis arthritis, polymyalgia rheumatica, collagenoses, and vasculitides.»

http://www.google.nl/patents/US8337908